Immunovations is a biotech start-up focused on developing the next generation of cancer vaccine adjuvant: Granulysin. Granulysin has outperformed traditional vaccine adjuvants like GM-CSF in immune stimulation in mice and represents a potential breakthrough in vaccine efficacy. We are collaborating with a strategic partner whom holds patent rights to dozens of cancer-specific antigens in an effort to deliver the next generation cancer vaccine.